Antibacterial drugs constitute chemicals either obtained from a natural source or synthesized in a laboratory that kill or inhibit the growth of various bacterial strains. These drugs have been grouped into eight major classes: aminoglycosides, β-lactams, tetracycline, sulfonamides, quinolones, fluoroquinolones, macrolides, and phenicols. Aminoglycosides is a class of bactericidal antibiotics that inhibit bacterial protein synthesis. These agents bind irreversibly to the 30S bacterial ribosome subunit and interfere with the reading of the genetic code, halt translation that results in inhibition of protein synthesis and ultimately cause cell death. Generally, aminoglycosides show bactericidal activity against aerobic gram negative bacteria and are not active against gram positive or anaerobic gram negative bacteria. Hence, aminoglycosides are often used in combination with a β-lactam to treat gram positive bacterial infections that allows penetration of aminoglycosides into the bacterial cytoplasm.
Aminoglycosides are useful as antibacterial agents with rapid bactericidal activity; however, usage is limited due to potential side effects as these agents are known to cause ear or kidney damage. The aminoglycosides class of antibiotics consists of a wide range of antibiotics such as tobramycin, amikacin, neomycin, gentamycin, streptomycin, kanamycin, and paromomycin. Of the above mentioned agents, tobramycin, gentamicin, and amikacin are the most frequently prescribed drugs. These agents resemble each other in antibacterial activity due to similar toxicity and pharmacokinetics. Drivers of the aminoglycosides market include increase in number of generic drugs available in the segment which can be utilized to treat a range of bacterial infections, persistent demand among consumers, and beneficial characteristics such as easy tissue penetration with little or no side effects. This market is highly fragmented, where a lot of generic drugs are available. These will continue to drive the market. However, patient expiry of drugs is a major restraint of the global aminoglycosides market.
The global aminoglycosides market can be segmented based on type of drug, distribution channel, and region. In terms of type of drug, the market can be categorized into tobramycin, amikacin, neomycin, gentamycin, streptomycin, kanamycin, paromomycin, verdamicin, astromicin and hygromycin B. Based on distribution channel, the global aminoglycosides market can be classified into hospital pharmacies, retail pharmacies, online pharmacies, and clinics.
In terms of region, the global aminoglycosides market can be segmented into North America, Europe, Asia Pacific, Latin America, and Rest of the World. Expanding health care infrastructure, rise in disposable income, and large percentage of geriatric population in emerging economies such as India and China are the factors expected to play a key role in representing Asia Pacific as one of the most attractive regions for manufacturers operating in the aminoglycosides market. Presence of leading generics manufacturers, low cost of clinical trials, and rapidly growing pharmaceutical industries is likely to propel the market in the region. New drugs are usually launched in the U.S. or Europe prior to their entry in other parts of the world. Hence, early market initiation in these countries as compared to other regions results in larger market share of North America and Europe. Moreover, increase in incidence of gram negative bacteria in North America is major factor attributed to the dominance of this region in the aminoglycosides market. A report published by the Centers for Disease Control and Prevention (CDC) in 2013 stated that over 2 million people suffer from antibiotic-resistant infections in the U.S. every year, and an estimated 23,000 deaths associated with these infections are reported each year. Hence, the global aminoglycosides market is expected to expand at a significant rate during the forecast period.
Major players in the global aminoglycosides market are GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Pfizer, Inc., and Bayer AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.